Epstein bullish on Gilenya after strong Q2
This article was originally published in Scrip
Executive Summary
David Epstein, head of Novartis Pharmaceuticals, urged analysts to take a rosier view of the ex-US prospects for its multiple sclerosis drug Gilenya (fingolimod) after the product turned in healthy growth in the second quarter. "I believe people still have expectations which are too low for this very, very important brand for us," he declared, pointing out that the in the first half of 2012 ex-US sales grew by 94% compared with the end of 2011.